Duchenne-izomdisztrófia: vizsgálatok itt: Egyesült Királyság
17 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
- Where
- Newcastle, Oxford
- Életkor
- 7 év to 16 év
- People
- 70 worldwide
- Run by
- Avidity Biosciences, Inc.
See details and how to joinNCT07587242 - 2/3. fázisTaking peopleA Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
- Where
- London, Newcastle upon Tyne
- Életkor
- 6 év to 10 év
- People
- 77 worldwide
- Run by
- Genethon
See details and how to joinNCT07856329 · EU 2023-505187-11-00 - 2. fázisCsak meghívásosOpen-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- Where
- London, Newcastle, Salford
- People
- 260 worldwide
- Run by
- Edgewise Therapeutics, Inc.
See details and how to joinNCT06066580 - 1/2. fázisTaking peopleA Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
- Where
- Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
- Életkor
- 4 év to 20 év
- People
- 24 worldwide
- Run by
- Entrada Therapeutics, Inc.
See details and how to joinNCT07037862 · EU 2024-517584-23-00 - 1/2. fázisTaking peopleA Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
- Where
- Leeds, Liverpool, London, Manchester, Oxford
- Életkor
- 4 év to 20 év
- People
- 24 worldwide
- Run by
- Entrada Therapeutics, Inc.
See details and how to joinNCT07038824 · EU 2024-517499-39-00 - 3. fázisTaking peopleEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
- Where
- Glasgow, Newcastle upon Tyne, Oxford
- Életkor
- 9 év to 17 év
- People
- 138 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT05933057 · EU 2023-503521-19-00 - 2. fázisCsak meghívásosAn Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
- Where
- London
- Életkor
- 4 év to 64 év
- People
- 18 worldwide
- Run by
- BioMarin Pharmaceutical
See details and how to joinNCT07573631 · EU 2024-511656-41-00 - 1/2. fázisTaking peopleA Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
- Where
- London
- Életkor
- 0 év to 17 év
- People
- 60 worldwide
- Run by
- Solid Biosciences Inc.
See details and how to joinNCT06138639 · EU 2024-514501-57-00 - 2. fázisNot yet taking people in Egyesült KirályságLong-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
- Where
- Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
- Életkor
- 4 év to 20 év
- People
- 80 worldwide
- Run by
- Entrada Therapeutics, Inc.
See details and how to joinNCT07682129 · EU 2025-525124-10-00 - No phaseTaking peopleA Remote Study Using Technology to Assess Outcomes in DMD
- Where
- Oxford
- Életkor
- 1 év to 3 év
- People
- 60
- Run by
- University of Oxford
See details and how to joinNCT07423026 - 2. fázisCsak meghívásosOpen-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
- Where
- Headington
- People
- 175 worldwide
- Run by
- Wave Life Sciences USA, Inc.
See details and how to joinNCT07209332 - No phaseTaking peopleNatural History of Duchenne Muscular Dystrophy
- Where
- London, Newcastle
- Életkor
- 4 év to 9 év
- People
- 220 worldwide
- Run by
- Genethon
See details and how to joinNCT03882827 - 3. fázisCsak meghívásosA Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
- Where
- London, Newcastle upon Tyne, Oxford
- Életkor
- Up to 64 év
- People
- 400 worldwide
- Run by
- Sarepta Therapeutics, Inc.
See details and how to joinNCT05967351 · EU 2023-505043-39-00 - 2/3. fázisTaking peopleGivinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- Where
- Gobowen, Liverpool, London, Newcastle upon Tyne
- Életkor
- 7 év and over
- People
- 206 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT03373968 - 2. fázisNot yet taking people in Egyesült KirályságRepurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age
- Where
- London
- Életkor
- 6 év to 18 év
- People
- 12
- Run by
- Sebastiano Lava
See details and how to joinNCT06643442 - 2. fázisTaking peoplePharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
- Where
- Leeds, London, Newcastle upon Tyne, Oxford
- Életkor
- 2 év to 6 év
- People
- 18 worldwide
- Run by
- Italfarmaco
See details and how to joinNCT06769633 - No phaseNot yet taking people in Egyesült KirályságThe U.K. NorthStar Clinical Network
- Where
- Aberdeen, Belfast, Birmingham, Bristol, Cambridge, Cardiff, Dundee, Glasgow, Lancaster, Leeds, Leicester, Liverpool, London, Manchester, Newcastle, Nottingham, Oswestry, Oxford, Plymouth, Sheffield, Southampton, Swansea
- Életkor
- Up to 99 év
- People
- 300
- Run by
- University College, London
See details and how to joinNCT06711692